Holen Sie sich die Stockscreener-App
4.74
3.04%
0.14
Handel nachbörslich:
4.74
Y Mabs Therapeutics Inc Aktie (YMAB) Neueste Nachrichten
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World
How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com
Oppenheimer Adjusts Target Price for Y-mAbs Therapeutics (YMAB) - GuruFocus
Y-mAbs Therapeutics (YMAB) Target Price Lowered by Oppenheimer | YMAB Stock News - GuruFocus
Oppenheimer Adjusts Price Target on Y-mAbs Therapeutics to $15 From $20, Maintains Outperform Rating - marketscreener.com
Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline - TipRanks
Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Transcript : Y-mAbs Therapeutics, Inc.Special Call - marketscreener.com
Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating - marketscreener.com
Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress - TipRanks
Y-mAbs Therapeutics Announces Positive Phase 1 Trial Results for GD2-SADA in Metastatic Solid Tumors and Expands Radiopharmaceutical Pipeline - Nasdaq
Clinical Trial Success: Y-mAbs Breakthrough in Cancer Treatment Shows Promise with Novel Radiopharmaceutical - Stock Titan
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025 - MSN
Y-mAbs Therapeutics, Inc. Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - marketscreener.com
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - The Manila Times
Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting - Nasdaq
Y-mAbs Advanced Cancer Trial Breakthrough: Key Data Coming for Revolutionary GD2-SADA Treatment - Stock Titan
Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles - Investing.com Canada
Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles By Investing.com - Investing.com South Africa
What is HC Wainwright’s Forecast for YMAB FY2026 Earnings? - Defense World
HC Wainwright Issues Pessimistic Estimate for YMAB Earnings - Defense World
Caligan Partners LP Increases Stake in Y-mAbs Therapeutics Inc - GuruFocus
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright - Defense World
What 7 Analyst Ratings Have To Say About Y-mAbs Therapeutics - Benzinga
H.C. Wainwright Adjusts Price Target for Y-mAbs Therapeutics (YM - GuruFocus
Price T Rowe Associates Inc. MD Cuts Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
FY2025 EPS Estimates for YMAB Increased by Analyst - Defense World
Formulation Is Key For Y-mAbs' Self-Assembling Antibody - Bioprocess Online
Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Oppenheimer Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Q2 EPS Estimates for Y-mAbs Therapeutics Cut by Wedbush - Defense World
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates - MSN
Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook - TipRanks
Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Y-mAbs Therapeutics (YMAB) Maintains "Outperform" Rating, PT Low - GuruFocus
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Y-mAbs Therapeutics outlines Q2 revenue guidance of $17M–$19M amid DANYELZA NCCN guideline inclusion and expanded ex-U.S. growth - MSN
Y-mAbs Therapeutics (YMAB) Maintains - GuruFocus
Y-mAbs Therapeutics (YMAB) Sees Target Price Reduced Amid Revenu - GuruFocus
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Securities Adjusts Y-mAbs Therapeutics Price Target to $14 From $18, Maintains Buy Rating - marketscreener.com
Dimensional Fund Advisors LP Decreases Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
YMAB Plans to Sustain Operations with Current Cash Reserves Unti - GuruFocus
Y-mAbs Therapeutics (YMAB) Price Target Lowered by Truist Securities | YMAB Stock News - GuruFocus
Y-mAbs (YMAB) Exceeds Revenue Expectations and Advances Strategi - GuruFocus
Y-mAbs Therapeutics Reports Q1 2025 Financial Results - TipRanks
Transcript : Y-mAbs Therapeutics, Inc., Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Y-mAbs Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
UnitedHealth Group CEO steps down; suspends 2025 outlook on higher-than-expected medical costs - The Globe and Mail
Y-mAbs Therapeutics, Inc. SEC 10-Q Report - TradingView
Y-mAbs Therapeutics Reports First Quarter 2025 Financial Results - TradingView
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 - The Manila Times
6.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):